European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Milan, Italy 28 September 2026 - 02 October 2026
Survodutide reduces body weight, improves cardiometabolic parameters in people with obesity & T2D
Survodutide, a glucagon receptor–glucagon-like peptide-1 (GLP-1) receptor dual agonist, provides sustained weight loss and improves glycaemic control and other cardiometabolic parameters in individuals with obesity and type 2 diabetes (T2D), primary results of the phase III SYNCHRONIZE-2 trial have shown.
Survodutide preferentially reduces metabolically harmful fat in obesity
Survodutide preferentially reduces metabolically harmful fat while largely preserving lean mass and muscle mass, according to new data from a body composition substudy of the phase III SYNCHRONIZE-1 trial involving adults with obesity without diabetes.
CGM initiation reduces hospitalizations for acute diabetes events
In an observational study, the rates of hospitalizations for acute diabetes events (ADEs) decreased following the initiation of the FreeStyle Libre (FSL) continuous glucose monitoring (CGM) system in adults with type 2 diabetes (T2D).
Retatrutide poised to be the next weight-loss option for T2D with obesity
In the phase III TRIUMP-2 trial, retatrutide improves glycaemic control and reduces body weight in adults with type 2 diabetes (T2D) who are overweight or have obesity, potentially expanding weight-loss options for this population.
Switch to oral semaglutide benefits patients with overweight, obesity
Individuals with overweight or obesity lost a significant amount of weight 3 months after switching from an injectable formulation of semaglutide or tirzepatide to oral semaglutide, findings from the real-world OCTANE trial have shown. The switch was also associated with high treatment adherence and satisfaction.
